Welcome to our dedicated page for BIOTRICITY news (Ticker: BTCY), a resource for investors and traders seeking the latest updates and insights on BIOTRICITY stock.
Biotricity, Inc. (BTCY) is a medical technology company at the forefront of healthcare innovation. Specializing in biometric data monitoring solutions, Biotricity aims to improve healthcare by developing remote monitoring solutions for chronic disease prevention and management. Its premier product, Bioflux, is an ECG monitoring system used by physicians to diagnose and monitor cardiac patients remotely. Biotricity's Biolife solution extends medical-grade monitoring to the consumer market, empowering users to self-manage chronic conditions through lifestyle changes. With a focus on preventive healthcare, Biotricity's R&D efforts aim to put health management directly into the hands of individuals, easing the burden on the healthcare system.
Rhea-AI Summary
RedChip Companies will air interviews with Better Therapeutics, Inc. (Nasdaq:BTTX) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. Better Therapeutics offers a groundbreaking approach to managing cardiometabolic diseases with its FDA-authorized product AspyreRx™, showcasing significant outcomes in treating type 2 diabetes. Biotricity revolutionizes cardiac care with remote diagnostic solutions, capturing an 8% market share in cardiology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
-
Rhea-AI Summary
Biotricity Inc. (BTCY) receives Health Canada approval to enter the US $1.56 billion Canadian Cardiology Devices market, aiming to revolutionize cardiovascular health solutions. The approval of Biotres underscores the company's commitment to reshaping healthcare through innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.7%
Tags
-
Rhea-AI Summary
Biotricity Inc. (NASDAQ: BTCY) reports strong financial results for Q3 FY24, showcasing topline growth, improved margins, lower costs, and a path to breakeven. Revenue increased by 21% to $2.97 million, with a gross margin of 73%. The net loss decreased by 36% YOY to $3.0 million. The company focuses on long-term growth, leveraging data intelligently, and developing the Cardiac AI Cloud Platform for predictive monitoring.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.01%
Tags
Rhea-AI Summary
Biotricity Inc. (NASDAQ:BTCY) to host Third Quarter Fiscal Year 2024 Financial Results and Business Update Call on February 21, 2024. CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou to provide insights. Investors can access the webcast for updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Biotricity Inc. (BTCY) announces record gross margins of 73% and improved operational efficiency in its fiscal third quarter 2024 results. The company focuses on subscription-based revenue, margin improvement, and operational efficiency enhancements to achieve breakeven. Dr. Waqaas Al-Siddiq, CEO, highlights revenue growth, operational efficiency, and data utilization to drive better patient outcomes and healthcare savings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
-
Rhea-AI Summary
Biotricity Inc. (BTCY) expands its Cardiac AI Cloud platform to support predictive monitoring and earlier interventions. The company has analyzed over 360 billion heartbeats and helped diagnose over 200,000 patients, with products used in 500+ US centers. The expansion aims to enhance existing products, improve operational efficiency, and support physicians with automated analysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.88%
Tags
Rhea-AI Summary
Biotricity Inc. (Nasdaq:BTCY) reports a 21.4% YOY revenue increase in Q2-FY24 to $2.9 million, with significant improvements in gross margins and a 22% reduction in SG&A. Recurring technology fees, customer device sales, continue to trend upwards, and net loss decreases by 21%. The company's CEO highlights the success of its Bioflux and Biotres products in monitoring atrial fibrillation and introduces AI-driven solutions to redefine medical diagnostics and patient care. The Q2-FY24 Financial Highlights and Operating Highlights demonstrate substantial growth and expansion in the company's services and products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Biotricity Inc. (Nasdaq:BTCY) announces improved margins, reduced selling expenses, and lower operating losses. The company will host its Second Quarter Fiscal Year 2024 Financial Results and Business Update Call on November 14, 2023. Investors can access the webcast and a replay via the Biotricity website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.11%
Tags
-
Rhea-AI Summary
Biotricity Inc. announces the expansion of its Biotres product platform with the introduction of Biotres Pro, which includes cellular backup for offline connectivity. The company has also filed a patent application for its cutting-edge 3 channel technology. With the addition of Biotres Pro, Biotricity now has the most comprehensive remote cardiac monitoring portfolio in the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.68%
Tags
Rhea-AI Summary
Biotricity files patent for Bioheart device, a wearable heart monitoring solution. The patent safeguards Bioheart's technology, design, and form factor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
FAQ
What is the current stock price of BIOTRICITY (BTCY)?
The current stock price of BIOTRICITY (BTCY) is $0.28 as of December 20, 2024.
What is the market cap of BIOTRICITY (BTCY)?
The market cap of BIOTRICITY (BTCY) is approximately 14.3M.
What is Biotricity, Inc.?
Biotricity, Inc. is a medical technology company focused on developing biometric data monitoring solutions for chronic disease prevention and management.
What are some of Biotricity's products?
Biotricity's premier product is Bioflux, an ECG monitoring system used for diagnosing and remotely monitoring cardiac patients. The company also offers Biolife, a consumer-focused solution for self-managing chronic conditions.
What is the vision of Biotricity, Inc.?
Biotricity aims to empower individuals by providing innovative solutions for preventive healthcare, ultimately enabling users to take control of their health and manage critical conditions effectively.
How does Biotricity contribute to the healthcare industry?
Biotricity's focus on remote monitoring and chronic care management bridges the gap in healthcare services, offering diagnostic and post-diagnostic solutions for chronic conditions, particularly in the cardiology sector.
BIOTRICITY INC
Nasdaq:BTCY
BTCY Rankings
BTCY Stock Data
14.29M
14.43M
40.89%
2.19%
2.07%
Medical Devices
Surgical & Medical Instruments & Apparatus
United States of America
REDWOOD CITY